A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

NCT05265728 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Due to sponsor decision, not for efficacy or safety reasons.

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Natalizumab

Sponsor

Biogen